Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye
To investigate that the efficacy of 3% DE-089 ophthalmic solution (one drop at a time, 6 times daily, 4 weeks topical administration), in comparison to 0.1% sodium hyaluronate ophthalmic solution (0.1% HA) (one drop at a time, 6 times daily, 4 weeks topical administration), is at least non-inferior in the change in fluorescein staining score, and is superior in the change in Rose bengal score, in a multicenter, double-masked, parallel-group comparison study. Safety profile will likewise be compared.
Drug: 3% DE-089 ophthalmic solution
Drug: 0.1% sodium hyaluronate ophthalmic solution
|Official Title:||Double-masked Comparison Study of DE-089 Ophthalmic Solution in Patients With Dry Eye (Multi-center Study, in Comparison to 0.1% Sodium Hyaluronate Ophthalmic Solution) - Phase III Confirmatory Study -|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01240382
|Santen study sites|